Serum gets DCGI nod for Phase 2 & 3 trials

Credit: IndiaTimes- Published on August 3, 2020
India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford University Covid-19 vaccine candidate.

Video credit: ANI
Published on August 4, 2020 -  02:24
COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR
Director General of Indian Council of Medical Research, Dr Balram Bhargava on August 04 stated that Oxford vaccine, being manufactured by Serum Institute of India, got approval for phase 2 and 3 clinical trials which are starting within a week at 17 sites. Earlier, the Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford vaccine.

You are here


💡 newsR Knowledge: Other News Mentions

Serum (blood)

Component of blood which does not contain cells or clotting factors
The government may need Rs 80,000 crore over the next one year for distribution of Covid-19 vaccine and immunization of the country’s population, Adar..
Credit: IndiaTimes - Published 5 days ago



Pune

Place in Maharashtra, India
A Pune Municipal Corporation (PMC) official said the two accused doctors were hired by an agency that is managing the said facility.
Credit: DNA - Published 3 days ago

It is to be noted that the Serum Institute of India is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford..
Credit: DNA - Published 4 days ago



Related videos from verified sources

Covid vaccine: Covaxin phase 3 trials on 3,000 people in UP, says minister 02:29
Credit: HT Digital Content - Published 1 day ago 


Bharat Biotech will involve 3,000 people for phase-III trials of COVID vaccine in UP 01:36
Credit: ANI - Published 2 days ago 


Johnson & Johnson's COVID-19 Vaccine Enters Phase 3 US Trials 01:22
Credit: Cover Video STUDIO - Published 1 week ago 


Related news from verified sources

India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford...
on August 3, 2020 • IndiaTimes

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India for conducting phase 2 and 3 human clinical trials of the Oxford...
on August 3, 2020 • IndiaTimes

You might like